



Synthesis and Biological Activity of a Model Disaccharide Containing a Key Unit in Heparin for Binding to Platelets

Yasuo Suda^{1*}, Karyn Bird², Takaaki Shiyama¹, Shuhei Koshida¹, Dalila Marques², Koichi Fukase¹, Michael Sobel², and Shoichi Kusumoto¹

¹Department of Chemistry, Faculty of Science, Osaka University, Toyonaka, Osaka 560, Japan

²Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA


Abstract: To determine the specific site(s) in heparin necessary for binding to platelets, synthesis of a model compound containing the disaccharide sequence, O-(2-deoxy-2-sulfamido-6-O-sulfo- α -D-glucopyranosyl)-(1 \rightarrow 4)-2-O-sulfo- α -L-idopyranuronic acid, found in heparin was performed by α -selective glycosidation using a phenyl thioglycoside as a donor. The compound inhibited ¹²⁵I-labelled heparin binding to human platelets to a greater extent than a heparin-derived disaccharide, obtained by the heparinase I digestion, yet contained the same number of sulfate groups per molecule.

Heparin, structurally a very heterogenous sulfated polysaccharide, has been used as an anticoagulant for over half a century.¹ Recently, however, it has been pointed out that pharmaceutical heparin binds to platelets and may directly alter platelet function and induce immuno sensitization,² which are undesirable side effects. Low molecular weight heparins (LMWHs), which are obtained by fractionation or depolymerization of commercial grade heparin and have lower average molecular weights (MW<10,000) than the parent heparin, possess diverse platelet reactivities,³ but the structural basis of these differences is not clearly understood. We have shown that different methods of depolymerization yield LMWHs with disparate platelets affinities. Periodate derived LMWHs possess a higher platelet binding activity than comparable LMWHs derived by either heparinase I or nitrous acid depolymerization.⁴ By considering the mechanism of depolymerization of these three methods, we predicted that a disaccharide sequence in heparin, O-(2-deoxy-2-sulfamido-6-O-sulfo- α -D-glucopyranosyl)-(1 \rightarrow 4)-2-O-sulfo- α -L-idopyranuronic acid (abbreviated as NS6S-I2S), may be a key disaccharide in heparin responsible for heparin binding to platelets.⁴ To confirm this prediction and to develop a clearer understanding of the interaction between heparin and platelets at the molecular level, we prepared a novel synthetic disaccharide, [methyl O-(2-deoxy-4-O-methyl-2-sulfamido-6-O-sulfo- α -D-glucopyranosyl)-(1 \rightarrow 4)-2-O-sulfo- α -L-idopyranosid]uronic acid (**1**), containing NS6S-I2S.

The synthesis of the model disaccharide **1** was carried out as shown in the scheme. The key point for the synthesis was to form an α (1-4) linkage between the D-glucosamine and L-idouronic acid moieties. An azide derivative was used for the precursor of the D-glucosamine unit, instead of using D-glucosamine itself, to prevent the undesirable β -linkage.⁵ According to the method reported by Carlson,⁶ 1,6:2,3-dianhydro-3-O-methyl-D-glucose (**2**) was prepared. An azide group was introduced into the 2-position by reacting **2** with lithium azide.⁵ The 3-hydroxyl group, which should not be O-sulfated at a later stage of synthesis, was

protected by a benzyl group to get the corresponding 1,6-anhydro-D-glucose derivative **3**. Compound **3** was reacted with phenylthiotrimethylsilane in the presence of zinc iodide,⁷ followed by the hydrolysis of the 6-O-trimethylsilyl group with potassium carbonate in a mixture of tetrahydrofuran and methanol (1/1, v/v). Since the 6-O-trichloroethoxycarbonyl (Troc) group was shown to be effective for an α -predominant glycosidation in our previous work,⁸ the compound was converted to a Troc-derivative to obtain the glycosyl donor **4**.

The L-iduronic acid derivative **5** was prepared from D-glucose using a modification of the procedure described by Jacquinet et al.⁹ The 1,2-O-isopropylidene protective group was removed by 90% aqueous trifluoroacetic acid (r.t. for 30 min). During this acid treatment, the furanosyl derivative was converted to the pyranose form, methyl 3-O-benzyl- α - and - β -idopyranuronate, which was isolated with a yield of 68%. The L-idose derivative **6** was obtained by the treatment with benzoyl chloride (yield 63% from compound **5**). Compound **6** was converted to the corresponding bromide with titanium bromide. To fix the α -pyranosyl structure of the L-idose unit as it is in heparin, the bromide of compound **6** was reacted with methanol in the presence of silver trifluoromethanesulfonate, thereby producing the methyl α -L-idopyranoside. The 2-O- and 4-O-benzoyl groups were then removed to produce the glycosyl acceptor **7**.



Scheme

Since we found that the reactivity of the 2-hydroxyl group of **7** was lower than the 4-hydroxyl group from the preliminary experiments, **7** was glycosylated without further protection. The coupling of **4** with **7** was effected using *N*-bromosuccinimide and silver perchlorate in ether at -20°C .¹⁰ After the acetylation of the hydroxyl group(s) of the glycosylated products, the desired $\alpha(1-4)$ linked disaccharide **8** was purified by silica-gel chromatography with 40% yield. In the coupling reaction, $\alpha(1-2)$ linked disaccharide and $\alpha(1-2):\alpha(1-4)$ linked trisaccharide were also obtained in low yields (13 and 14%, respectively). It was remarkable, however, that the linkages were all α -configuration. This high anomeric selectivity may be due to the effect of the 6-O-Troc group in the glycosyl donor, in addition to the effects of the ether as a solvent and perchlorate as a reagent.¹⁰

The 2-O-acetyl group and 6'-O-Troc group of **8** were removed by sodium methoxide, then the 2- and 6'-hydroxyl groups were O-sulfated using a sulfur trioxide trimethylamine complex in dimethylformamide at 50°C for 6 h.¹¹ The product was neutralized by passage through an ion-exchange resin (Dowex 50Wx8, Na^+ form) to obtain **9**. The sulfation of 2-O- and 6'-O-positions was confirmed by the changes in chemical shifts in the ^1H -NMR spectra (δ in CDCl_3 at 30°C): H-1 (4.91 \rightarrow 4.62), H-2 (3.61 \rightarrow 5.08), H-3 (3.91 \rightarrow 4.28) and H-6' (3.73 \rightarrow 4.19). After the treatment of **9** with a mixture of methanol and 5 M aqueous sodium hydroxide (5/1, v/v) at room temperature for 2 h, the resulting compound was hydrogenated at 6 kg/cm² for 4 days in the presence of palladium black in tetrahydrofuran/acetic acid/water (4/1/2, v/v/v). Finally N-sulfation was performed using a sulfur trioxide pyridine complex in aqueous sodium hydroxide (pH 9.5) at room temperature for 4 days. Formation of the desired trisulfated disaccharide **1** was confirmed by ^1H -NMR and negative mode FAB-MS: m/z 688.3 [a pseudo-molecular ion ($\text{M}-\text{Na}$)-]. Furthermore, a significant change in the chemical shift due to the N-sulfation was observed for H-2' (2.85 \rightarrow 3.24).

The binding activity of **1** to platelets was evaluated by comparison with a purified disaccharide **10** (obtained by exhaustive heparinase I digestion of heparin) and a commercial heparin (from porcine intestine, Nacalai tesque, Kyoto, Japan). This structure **10** was based on the mode of action of heparinase I and determined by elemental analysis and molecular weight analysis by negative phase FAB- and ESI-MS. Homogeneity of **10** was confirmed by chromatographic profiles of high performance gel-permeation and capillary electrophoresis. The heparin-platelet competitive binding assay was performed according to a modification of a method reported previously⁴ using ^{125}I -labelled heparin.¹² The results of the heparin-platelet binding assay are shown in Fig. 1.

Our previous work showed that platelet binding activity had both molecular weight and structural dependence.⁴ In Fig. 1 both synthetic and heparinase-digested disaccharides (**1** and **10**) showed decreased platelet binding activity when compared to the commercial heparin (MW 17,000). The synthetic disaccharide **1**, however, demonstrated a greater inhibitory activity of ^{125}I -labelled heparin binding to platelets, thus higher platelet affinity, than the heparinase-digested disaccharide **10**, although they both contain the same number of sulfates per molecule (three). These results suggest that the unique disaccharide sequence (NS6S-I2S) contributes to specific heparin-platelet interactions. This disaccharide unit is destroyed by the specific heparinase I-digestion of heparin. The findings described here confirm our previous prediction that the NS6S-I2S sequence is a key disaccharide for heparin binding to platelets.

Acknowledgements: The authors are grateful to Mr. Masaru Miyagi at Takara Shuzo Co., Ltd (Shiga, Japan) for the analyses by ESI-MS. This work was supported in part by Organic Synthetic Society TEIJIN award (YS), by the Grant-in Aid for International Scientific Research (No. 06044138, YS) and the Grant-in Aid for Scientific Research (No. 05403035, SK) from the Ministry of Education, Science, Sports and Culture, Japan and by grant HL39903 from the National Institute of Health, USA (MS).




Fig. 1 Binding competition activity of disaccharides and commercial heparin.

References and Notes

1. Crafoord, C. *Acta Chirurgica Scandinavica*, **1939**, 82, 319-335.
2. Sobel, M. *Perspec. Vasc. Surg.*, **1992**, 5, 1-30.
3. Holmer, E. In: *Heparin, Chemical and Biological Properties, Clinical Applications* (Lane, D. A. and Lindahl, U. eds.), CRC Press, Inc. Boca Raton, Florida, **1989**, pp 575-596.
4. Suda, Y.; Marques, D.; Kermode, J. C.; Kusumoto, S.; Sobel, M. *Throm. Res.*, **1993**, 69, 501-508.
5. Banoub, J.; Boullanger, P.; Lafant, D. *Chem. Rev.*, **1992**, 92, 1167-1195.
6. Carlson, L.J. *J. Org. Chem.*, **1965**, 30, 3953-3955.
7. Wang, L.-X.; Sakairi, N.; Kuzuhara, H. *J. Chem. Soc. Perkin Trans I*, **1990**, 1677-1682.
8. Fukase, K.; Yoshimura, T.; Kotani, S.; Kusumoto, S. *Bull. Chem. Soc. Jpn.*, **1994**, 67, 473-482.
9. Jacquinot, J. -C.; Petitou, M.; Duchaussoy P.; Lederman I.; Choay, J.; Torri, G.; Sinaÿ, P. *Carbohydr. Res.*, **1984**, 130, 221-241.
10. Activation of thioglycosides with N-bromosuccinimide and strong acid salts was reported (Fukase, K.; Hasuoka, A.; Kinoshita, I.; Aoki, Y.; Kusumoto, S. *Tetrahedron*, **1995**, 51, 4923-4932). The combination of N-bromosuccinimide (NBS) and silver perchlorate in ether was effective for α -selective glycosidation with 6-O-Troc thioglycosides (Fukase, K.; Kinoshita, I.; Kanoh, T.; Hasuoka, A.; Aoki, Y.; Shiyama, T.; Koshida, S.; Suda, Y.; Kusumoto, S. Abstracts of XVIIth Japan Carbohydrate Symposium, Kyoto, July 1995, No. C-9).
11. Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Sinaÿ, P.; Jacquinot, J. -C.; Torri, G. *Carbohydr. Res.*, **1986**, 147, 221-236.
12. Sobel, M.; Ottenbrite, R. M.; Suda, Y. In: *Polymeric drugs and Drug Delivery Systems*. (Dunn, R. L. and Ottenbrite, R. M. eds.), ACS Books, Washington DC, **1991**, pp 60-70.

(Received in Japan 6 November 1995; revised 1 December 1995; accepted 7 December 1995)